Board of Directors

Charles J. Casamento, MBA, Chairman of the Board

Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  He was president and CEO of Osteologix from October 2004 until April 2007. Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and chairman.  In 2014 Questcor was acquired by Mallinckrodt for approximately $6 Billion. At RiboGene Inc. he was president, CEO and chairman and he was also co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). Indevus was eventually acquired by Endo for approximately $800 Million. He has held senior management positions at Genzyme Corporation, where he was Senior Vice President and General Manager for Biochemicals and Pharmaceuticals, American Hospital Supply, where he was Vice President of Business Development for the Critical Care Division, Johnson & Johnson, Hoffmann-LaRoche and Sandoz.   During his career he has been a Director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College. Mr. Casamento also serves as the Chairman of the company’s Audit Committee.

Committees

Committee Role
Audit Committee Member
Compensation Committee Member
Corporate Governance and Nominating Committee Member

John Glasspool, Director

John Glasspool is CEO and member of the Board of Directors of Anthos Therapeutics.  Mr. Glasspool is also a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated (NYSE: BXLT), formerly Baxter BioScience (NYSE: BAX).  Prior to joining Baxter in August 2012, Mr. Glasspool was Head of Region Europe and Novartis Vaccines & Diagnostics (NYSE: NVS), a member of the V&D Executive Committee. Mr. Glasspool served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012.  Previously, Mr. Glasspool was Head of Global Pricing & Market Access and Head of Global Commercial Operations in Novartis Pharma, where he led the functions in embedding the needs of customers and consumers for brands at all stages of their lifecycle development, launch, and in market. Mr. Glasspool joined Novartis as Head of Marketing for Neuroscience. He was promoted to Global Head Cardiovascular & Metabolism Business Franchise in 2006, during which time he grew the franchise sales over a three-year period.

Committees

Committee Role
Corporate Governance and Nominating Committee Chair
Compensation Committee Member

Paul Kelly, MBA, Director

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities, and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune Magazine All Star Analyst Team in 2000. Since 2007, Mr. Kelly has engaged in consulting for private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly holds an A.B. in biochemistry from Brown University, attended the University of Rochester School of Medicine, and received an M.B.A in finance from the William E. Simon School at the University of Rochester.

Committees

Committee Role
Compensation Committee Chair
Audit Committee Member

Eric T. Schmidt, Ph.D., Director

Eric T. Schmidt, Ph.D., is Chief Financial Officer of Allogene. He was previously Managing Director and Senior Biotechnology Analyst at Cowen and Company. During his two decades there, he was a highly trusted industry analyst whose work was recognized in polls conducted by Alpha Magazine, Institutional Investor, Reuters and The Wall Street Journal.  Prior to joining Cowen in 1998, Eric was a Vice President and Research Analyst covering the biotechnology sector for UBS Securities. Before joining UBS, he co-founded Cambridge Biological Consultants, a scientific consulting and research firm.  He holds a B.A. in chemistry from the University of Pennsylvania and a Ph.D. in biochemistry from the Massachusetts Institute of Technology, where he serves on the Visiting Committee for the Department of Biology.

Committees

Committee Role
Audit Committee Chair
Corporate Governance and Nominating Committee Member

Sergio Traversa, PharmD, MBA, Chief Executive Officer

Before joining Relmada, Dr. Traversa was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory roles. He has held financial analyst, portfolio management and strategic advisory positions at large U.S. investment firms specializing in healthcare, including Mehta and Isaly and Mehta partners, ING Barings, Merlin BioMed and Rx Capital. Dr. Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business Unit. He was also a member of the CNS team at Eli Lilly, where he participated in the launch of Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at Farmitalia Carlo Erba, the largest pharmaceutical company in Italy later sold to Pharmacia and now part of Pfizer. Dr. Traversa holds a Laurea degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York University Leonard Stern School of Business.